One-liner#

Osteoporosis management centers on fracture prevention through DEXA-guided risk stratification, bisphosphonate therapy for most patients meeting treatment thresholds, adequate calcium/vitamin D, fall prevention, and planned drug holidays after 3-5 years of treatment.

Quick nav#

• Definition and epidemiology
• Pathophysiology
• Clinical presentation
• Diagnostic workup
• Treatment
• Patient education
• Prognosis and monitoring
• Special populations
• When to refer
• Smartphrase snippets
• Related pages

Definition and epidemiology#

Diagnostic criteria#

WHO criteria (based on DEXA T-score at hip, femoral neck, or lumbar spine):

• Normal: T-score ≥ -1.0
• Osteopenia (low bone mass): T-score -1.0 to -2.5
• Osteoporosis: T-score ≤ -2.5
• Severe osteoporosis: T-score ≤ -2.5 with fragility fracture

Clinical osteoporosis can also be diagnosed by:

• Low-trauma (fragility) fracture of hip, spine, or distal forearm regardless of T-score
• Vertebral fracture identified on imaging (even if asymptomatic)

FRAX treatment thresholds (US-adapted):

• 10-year probability of hip fracture ≥3%, OR
• 10-year probability of major osteoporotic fracture ≥20%
• Use FRAX when T-score is in osteopenic range (-1.0 to -2.5) to guide treatment decisions

Epidemiology#

Osteoporosis affects approximately 10 million Americans, with another 44 million having low bone mass. Lifetime fracture risk: 50% for women, 20% for men over age 50. Hip fractures carry 20-30% one-year mortality in older adults. Vertebral fractures are the most common osteoporotic fracture but only one-third are clinically recognized.

Risk factors:

• Non-modifiable: age, female sex, white/Asian ethnicity, family history of hip fracture, personal history of fracture
• Modifiable: low body weight (BMI <20), smoking, excess alcohol (>3 drinks/day), low calcium/vitamin D intake, sedentary lifestyle
• Secondary causes: glucocorticoids (≥5mg prednisone equivalent for ≥3 months), hyperparathyroidism, hyperthyroidism, hypogonadism, malabsorption, chronic kidney disease, rheumatoid arthritis

Pathophysiology#

Mechanism (clinical understanding)#

Bone is continuously remodeled throughout life through a coupled process:

1. Osteoclasts resorb old bone (takes ~3 weeks)
2. Osteoblasts form new bone in the resorption cavity (takes ~3 months)

In osteoporosis, resorption exceeds formation:

• Peak bone mass is achieved by age 25-30
• After age 30, bone loss occurs at ~0.5-1% per year
• Postmenopausal women: estrogen withdrawal accelerates osteoclast activity; bone loss increases to 2-3% per year for 5-10 years after menopause
• Men: gradual testosterone decline contributes to slower bone loss

Why this matters clinically:

• Bisphosphonates work by inhibiting osteoclasts (anti-resorptive)—they slow bone loss but don’t build new bone
• Anabolic agents (teriparatide, romosozumab) stimulate osteoblasts—they actually build bone
• It takes 3-6 months to see effects of treatment because bone remodeling is slow
• Drug holidays are possible with bisphosphonates because they bind to bone and continue working after discontinuation

Secondary osteoporosis mechanisms:

• Glucocorticoids: directly inhibit osteoblasts, increase osteoclast lifespan, decrease calcium absorption, cause muscle weakness (fall risk)
• Hyperparathyroidism: PTH excess increases bone turnover with net bone loss
• Vitamin D deficiency: impaired calcium absorption leads to secondary hyperparathyroidism
• Malabsorption: celiac disease, gastric bypass reduce calcium and vitamin D absorption

How to explain to patients#

Your bones are living tissue that is constantly being broken down and rebuilt. Think of it like a road crew—one team tears up old pavement while another team lays new asphalt. In healthy bones, these teams work at the same pace.

In osteoporosis, the “tear down” team works faster than the “rebuild” team. Over time, your bones become thinner and more fragile, like a honeycomb with bigger holes. This makes them more likely to break, even from a minor fall or sometimes just from bending over.

The good news is that we can slow down the “tear down” team with medication. We can also help the “rebuild” team by making sure you get enough calcium and vitamin D. Exercise helps too—it signals your bones to stay strong.

Clinical presentation#

Characteristic symptoms#

Osteoporosis itself is silent—there are no symptoms until a fracture occurs.

Fracture presentations:

• Vertebral compression fracture: sudden onset mid-back pain after minimal trauma (bending, lifting, coughing); may be asymptomatic and found incidentally on imaging
• Hip fracture: groin or lateral hip pain after fall; inability to bear weight
• Distal radius (Colles) fracture: wrist pain/deformity after fall on outstretched hand
• Proximal humerus fracture: shoulder pain after fall

Signs suggesting undiagnosed osteoporosis:

• Height loss >1.5 inches (4 cm) from peak adult height
• Progressive thoracic kyphosis (“dowager’s hump”)
• History of fragility fracture (fracture from fall from standing height or less)

Physical exam findings#

Routine exam in osteoporosis:

• Measure height at every visit (compare to historical peak height)
• Assess kyphosis (increased thoracic curvature)
• Gait and balance assessment (fall risk)
• Muscle strength (proximal weakness suggests vitamin D deficiency or secondary cause)

After suspected vertebral fracture:

• Focal midline tenderness over affected vertebra
• Pain with percussion over spinous processes
• Limited spinal range of motion due to pain

Fall risk assessment:

• Timed Up and Go test: >12 seconds suggests increased fall risk
• Single-leg stance: inability to stand on one leg for 5 seconds indicates fall risk
• Vision, footwear, home safety assessment

Red flags#

• New severe back pain in patient with osteoporosis: vertebral fracture until proven otherwise
• Inability to bear weight after fall: hip fracture (even if x-ray initially negative—consider MRI)
• Hypercalcemia with osteoporosis: evaluate for primary hyperparathyroidism or malignancy
• Osteoporosis in premenopausal woman or man <50: always evaluate for secondary causes
• Rapid bone loss (>4% per year): evaluate for secondary causes, medication adherence, malignancy
• Multiple vertebral fractures despite treatment: consider treatment failure, secondary causes, or malignancy

Diagnostic workup#

Initial evaluation#

Who to screen with DEXA (USPSTF recommendations):

• All women ≥65 years
• Postmenopausal women <65 with risk factors (use FRAX or clinical judgment)
• Men ≥70 years (some guidelines) or with risk factors
• Anyone with fragility fracture
• Anyone starting or on long-term glucocorticoids (≥3 months)
• Anyone with conditions associated with bone loss

DEXA interpretation:

• T-score: compares patient’s BMD to young adult reference (used for postmenopausal women and men ≥50)
• Z-score: compares to age-matched reference (used for premenopausal women, men <50, children)
• Report lowest T-score from lumbar spine (L1-L4), total hip, or femoral neck
• Lumbar spine may be falsely elevated by degenerative changes, aortic calcification, or compression fractures

FRAX calculator (fractureriskassessment.org):

• Use for patients with osteopenia (T-score -1.0 to -2.5) to determine if treatment is warranted
• Inputs: age, sex, weight, height, prior fracture, parent hip fracture, current smoking, glucocorticoids, RA, secondary osteoporosis, alcohol ≥3/day, femoral neck BMD
• Output: 10-year probability of hip fracture and major osteoporotic fracture
• Treatment threshold: ≥3% hip fracture risk OR ≥20% major osteoporotic fracture risk

Baseline labs for all patients starting treatment:

• 25-hydroxyvitamin D: target ≥30 ng/mL; replete before starting bisphosphonates
• Calcium: rule out hypercalcemia (hyperparathyroidism) or hypocalcemia
• Creatinine/eGFR: bisphosphonates contraindicated if eGFR <30-35
• CBC: anemia may suggest malignancy or malabsorption
• TSH: hyperthyroidism accelerates bone loss

Additional labs if secondary cause suspected:

• PTH (if calcium abnormal or unexplained osteoporosis)
• Serum protein electrophoresis (SPEP) if multiple myeloma suspected (unexplained anemia, elevated protein, lytic lesions)
• Celiac panel (TTG-IgA) if malabsorption suspected
• 24-hour urine calcium (hypercalciuria or malabsorption)
• Testosterone (men with osteoporosis)

Confirmatory testing#

Vertebral fracture assessment (VFA) or spine imaging: Indicated when vertebral fracture would change management:

• Height loss >1.5 inches (4 cm) from peak or >0.8 inches (2 cm) from prior measurement
• Kyphosis
• Glucocorticoid use (≥5mg prednisone for ≥3 months)
• T-score ≤-1.0 with history of fragility fracture
• Age ≥70 (women) or ≥80 (men) with T-score ≤-1.0

VFA can be done at time of DEXA (lower radiation than x-ray, identifies moderate-severe fractures) Lateral thoracic and lumbar spine x-ray if VFA not available or inconclusive

When to refer for specialist workup#

Endocrinology referral:

• Premenopausal osteoporosis or men <50 with osteoporosis (evaluate secondary causes)
• Suspected secondary osteoporosis (hyperparathyroidism, Cushing’s, hypogonadism)
• Treatment failure (fracture on therapy or significant BMD decline despite adherence)
• Severe osteoporosis (T-score ≤-3.0 or multiple fractures) requiring anabolic therapy
• Complex cases (CKD stage 4-5, transplant patients)

Rheumatology referral:

• Glucocorticoid-induced osteoporosis management in complex inflammatory disease
• Osteoporosis with suspected inflammatory arthritis

What NOT to order#

• Bone turnover markers (CTX, P1NP) routinely: useful in research and specialty settings but rarely change primary care management; expensive and results vary with timing/fasting
• Repeat DEXA before 2 years: BMD changes slowly; earlier repeat rarely changes management (exception: glucocorticoid initiation)
• DEXA in young, healthy premenopausal women without risk factors: low yield; T-scores not validated in this population
• Whole-body bone scan for osteoporosis: this is for metastatic disease, not osteoporosis evaluation
• CT for BMD assessment: higher radiation than DEXA; quantitative CT (QCT) is specialized and not routine

Treatment#

Goals of therapy#

1. Prevent fractures—the primary goal; BMD improvement is a surrogate marker
2. Maintain or improve BMD (target: stable or increasing T-score)
3. Reduce fall risk through exercise, balance training, and home safety
4. Ensure adequate calcium and vitamin D for bone health and medication efficacy
5. Minimize treatment-related adverse effects through appropriate drug selection and monitoring

Treatment thresholds:

• T-score ≤-2.5 at hip, femoral neck, or lumbar spine
• T-score -1.0 to -2.5 (osteopenia) with FRAX ≥3% hip or ≥20% major osteoporotic fracture
• History of hip or vertebral fracture (regardless of T-score)
• Glucocorticoid use ≥3 months at ≥2.5mg prednisone equivalent daily (lower threshold)

Non-pharmacologic management#

Calcium intake:

• Target: 1000-1200 mg/day total (diet + supplements)
• Dietary sources preferred: dairy, fortified foods, leafy greens
• If supplementing: calcium carbonate (take with food) or calcium citite (can take without food; better for patients on PPIs or with achlorhydria)
• Do not exceed 2000 mg/day (cardiovascular concerns with high-dose supplements)
• Split doses: absorb better in doses ≤500 mg at a time

Vitamin D:

• Target: 25-OH vitamin D ≥30 ng/mL (some experts target 40-60 ng/mL)
• Maintenance: 800-2000 IU vitamin D3 daily for most adults
• Repletion for deficiency (<20 ng/mL): 50,000 IU vitamin D2 weekly × 8 weeks, then maintenance
• Recheck 25-OH vitamin D 8-12 weeks after starting repletion

Exercise:

• Weight-bearing exercise: walking, jogging, dancing, stair climbing (30 minutes most days)
• Resistance training: 2-3 times per week; improves muscle strength and BMD
• Balance exercises: tai chi, yoga, single-leg stands (reduce fall risk)
• Avoid high-impact activities or heavy spinal flexion in patients with vertebral fractures

Fall prevention:

• Home safety: remove throw rugs, improve lighting, install grab bars
• Vision correction
• Medication review: reduce sedatives, anticholinergics, antihypertensives causing orthostasis
• Assistive devices as needed (cane, walker)
• Physical therapy for gait and balance training

Lifestyle modifications:

• Smoking cessation (smoking accelerates bone loss)
• Limit alcohol to ≤2 drinks/day
• Adequate protein intake (1.0-1.2 g/kg/day)

Pharmacologic management#

First-line: Oral bisphosphonates#

Second-line: IV bisphosphonate#

Alternative agents#

Anabolic agents (specialist initiation)#

Anabolic agent principles:

• Reserved for severe osteoporosis (T-score ≤-3.0, multiple fractures, very high fracture risk)
• Limited duration (2 years for teriparatide/abaloparatide, 1 year for romosozumab)
• MUST follow with bisphosphonate or denosumab to maintain bone gains
• Usually initiated by endocrinology

Patient counseling points#

For bisphosphonates:

• “Take this medication first thing in the morning on an empty stomach with a full glass of plain water—not coffee, juice, or other beverages.”
• “Stay upright (sitting or standing) for at least 30 minutes after taking it, and don’t eat or drink anything else during that time. This prevents irritation to your esophagus.”
• “If you miss a dose, take it the next morning you remember, then go back to your regular schedule. Don’t take two doses in one day.”
• “Most people tolerate this well. Tell me if you have heartburn, difficulty swallowing, or chest pain.”

For denosumab:

• “This injection is given every 6 months. It’s very important not to miss doses or stop this medication without talking to me first.”
• “If we need to stop this medication, we’ll need to switch you to a different bone medication to prevent rapid bone loss.”

For calcium and vitamin D:

• “Think of calcium and vitamin D as the building blocks for your bones. The medication works better when you have enough of these.”
• “Try to get calcium from food first—dairy products, fortified orange juice, leafy greens. If you need a supplement, take it in divided doses with meals.”

For exercise and fall prevention:

• “Weight-bearing exercise like walking actually helps strengthen your bones. Try to walk for 30 minutes most days.”
• “Strength training is also important—it builds muscle that protects your bones and helps prevent falls.”
• “Falls are the main cause of fractures. Let’s talk about making your home safer—removing throw rugs, improving lighting, and installing grab bars in the bathroom.”

For expectations:

• “This medication prevents fractures, but you won’t feel any different taking it. We monitor your bone density every 2 years to make sure it’s working.”
• “After 5 years of treatment, we’ll discuss whether you can take a ‘drug holiday.’ Your bones store the medication, so it keeps working for a while after you stop.”

Monitoring and follow-up#

Initial follow-up (1-3 months after starting treatment):

• Assess medication tolerance and adherence
• Review proper administration technique for oral bisphosphonates
• Confirm vitamin D repletion if previously deficient

Ongoing monitoring:

• DEXA every 2 years while on treatment
• Height measurement at every visit
• 25-OH vitamin D annually (or as needed to maintain ≥30 ng/mL)
• Renal function periodically (especially before IV zoledronic acid)
• Dental exam before starting and periodically during treatment (ONJ risk)

Drug holiday assessment (after 5 years oral or 3 years IV bisphosphonate): Consider drug holiday if ALL of the following:

• No fractures during treatment
• T-score improved to >-2.5
• No very high fracture risk (e.g., glucocorticoid use, very low baseline T-score)

During drug holiday:

• Continue calcium, vitamin D, exercise, fall prevention
• DEXA every 2-3 years
• Restart treatment if: new fracture, significant BMD decline (>5%), or T-score returns to ≤-2.5

Denosumab: NO drug holiday

• Stopping denosumab causes rapid bone loss and rebound vertebral fractures
• If discontinuing, must transition to bisphosphonate (typically alendronate or zoledronic acid) for at least 1-2 years

Patient education#

What is this condition?#

Osteoporosis means your bones have become thin and weak. Think of healthy bone like a strong honeycomb. In osteoporosis, the holes in the honeycomb get bigger and the walls get thinner. This makes bones more likely to break.

Osteoporosis is called a “silent disease” because you can’t feel your bones getting weaker. Most people don’t know they have it until they break a bone from a minor fall or even just bending over.

The most common breaks happen in the spine, hip, and wrist. A broken hip is serious—it often requires surgery and can affect your ability to live independently.

What you can do#

Take your bone medication exactly as directed. For pills taken weekly, pick the same day each week and take it first thing in the morning with plain water. Stay upright for 30 minutes afterward.

Get enough calcium—aim for 1000-1200 mg per day from food and supplements combined. Good sources include milk, yogurt, cheese, fortified orange juice, and leafy greens.

Take vitamin D—most people need 800-2000 units per day. Your doctor will check your blood level to make sure you’re getting enough.

Exercise regularly. Walking, dancing, and climbing stairs help keep bones strong. Strength training with weights or resistance bands builds muscle that protects your bones.

Prevent falls. Remove throw rugs, improve lighting, and install grab bars in your bathroom. Wear sturdy shoes with non-slip soles.

When to seek care#

Call your doctor if you have new back pain, especially if it started suddenly. This could be a spine fracture.

Call if you fall and have pain in your hip, wrist, or anywhere else, even if you can still walk. Some fractures aren’t obvious right away.

Call if you have trouble swallowing, chest pain, or severe heartburn after taking your bone medication.

Call if you have jaw pain, loose teeth, or a sore in your mouth that won’t heal (rare side effect of bone medications).

Questions to ask your doctor#

• What is my bone density score and what does it mean?
• What is my risk of breaking a bone in the next 10 years?
• Which bone medication is best for me?
• How long will I need to take this medication?
• Am I getting enough calcium and vitamin D?
• What exercises are safe for me?
• How can I make my home safer to prevent falls?

Prognosis and monitoring#

Expected course#

Without treatment:

• Continued bone loss of 1-3% per year
• Increasing fracture risk with age
• Hip fracture risk doubles every 5-7 years after age 50
• Vertebral fractures often lead to additional vertebral fractures (vertebral fracture cascade)

With treatment:

• Bisphosphonates reduce vertebral fractures by 40-70% and hip fractures by 40-50%
• BMD typically stabilizes or improves within 1-2 years
• Fracture risk reduction begins within 6-12 months of treatment
• Benefits persist for years after stopping bisphosphonates (due to bone binding)

Factors affecting prognosis:

• Baseline fracture risk (prior fractures, very low T-score)
• Medication adherence (poor adherence is common and reduces efficacy)
• Fall risk (most fractures result from falls)
• Secondary causes (untreated secondary causes limit treatment response)

Monitoring parameters#

Complications to watch for#

Fractures despite treatment:

• Reassess adherence and proper administration
• Check vitamin D level
• Evaluate for secondary causes
• Consider treatment failure—may need anabolic therapy

Medication-related complications:

Bisphosphonates:

• GI intolerance (esophagitis, dyspepsia): ensure proper administration; consider IV if persistent
• Osteonecrosis of the jaw (ONJ): rare (<1/10,000 patient-years); higher risk with dental procedures, poor oral hygiene; maintain dental care
• Atypical femur fractures: rare; associated with prolonged use (>5 years); prodromal thigh pain; reason for drug holidays

Denosumab:

• Hypocalcemia: especially in CKD; ensure adequate calcium/vitamin D
• Rebound bone loss if stopped: must transition to bisphosphonate
• ONJ: similar risk to bisphosphonates

Special populations#

Elderly/geriatric#

Treatment considerations:

• Age alone is not a contraindication to treatment—fracture risk increases with age
• Fall prevention is paramount; address polypharmacy, vision, home safety
• Oral bisphosphonates may be difficult (30-minute upright requirement, cognitive impairment affecting adherence)
• IV zoledronic acid or denosumab may be preferred for adherence
• Simpler regimens preferred (weekly or less frequent dosing)

Beers criteria considerations:

• Bisphosphonates are NOT on Beers list—they are appropriate in elderly
• Avoid muscle relaxants for back pain (fall risk, anticholinergic effects)
• Review medications contributing to fall risk (sedatives, anticholinergics, antihypertensives)

Goals may differ:

• Focus on fracture prevention and maintaining independence
• Consider life expectancy when deciding on treatment duration
• In frail elderly with limited life expectancy, may prioritize fall prevention over pharmacotherapy

Dose adjustments:

• No age-based dose adjustments for bisphosphonates
• Ensure adequate renal function (eGFR ≥35)
• Start vitamin D repletion at standard doses

Chronic kidney disease#

Medication adjustments:

Special considerations:

• CKD-mineral bone disorder (CKD-MBD) complicates osteoporosis management in advanced CKD
• DEXA may not accurately reflect fracture risk in CKD
• Denosumab is preferred in CKD stage 4-5 (no renal clearance) but requires close calcium monitoring
• Consult nephrology or endocrinology for CKD stage 4-5
• Ensure vitamin D is repleted; may need active vitamin D (calcitriol) in advanced CKD
• Monitor for hypocalcemia, especially with denosumab

Other populations#

Glucocorticoid-induced osteoporosis:

• Lower treatment threshold: treat if T-score ≤-1.0 (not -2.5) or any prior fragility fracture
• Start treatment early: bone loss is most rapid in first 3-6 months of glucocorticoid use
• Bisphosphonates are first-line; teriparatide may be preferred for very high risk
• Continue treatment as long as glucocorticoids continue
• ACOG/ACR guidelines recommend treatment for anyone on ≥2.5mg prednisone equivalent for ≥3 months with moderate-high fracture risk

Premenopausal women:

• Use Z-score, not T-score (compare to age-matched, not young adult)
• Always evaluate for secondary causes (eating disorders, athletic amenorrhea, celiac, hyperparathyroidism)
• Bisphosphonates have long skeletal half-life—consider implications for future pregnancy
• Denosumab effects are reversible but rebound bone loss is a concern
• Refer to endocrinology for management

Men with osteoporosis:

• Evaluate for secondary causes: hypogonadism (check testosterone), alcohol use, glucocorticoids
• Treatment options same as women; bisphosphonates are first-line
• Testosterone replacement alone does not adequately treat osteoporosis—add bisphosphonate

Polypharmacy considerations:

• Calcium supplements may reduce absorption of levothyroxine, fluoroquinolones, tetracyclines—separate by 2-4 hours
• PPIs reduce calcium carbonate absorption—use calcium citrate instead
• Bisphosphonates have minimal drug interactions (but must be taken on empty stomach)
• Denosumab has no significant drug interactions
• Review medications contributing to bone loss: glucocorticoids, PPIs (long-term), aromatase inhibitors, androgen deprivation therapy, anticonvulsants

When to refer#

Specialist referral criteria#

Endocrinology referral:

• Premenopausal osteoporosis or men <50 with osteoporosis
• Suspected secondary osteoporosis requiring workup
• Treatment failure (fracture on therapy, significant BMD decline despite adherence)
• Severe osteoporosis requiring anabolic therapy (T-score ≤-3.0, multiple fractures)
• Complex cases: CKD stage 4-5, transplant recipients, multiple comorbidities
• Denosumab discontinuation planning

Rheumatology referral:

• Glucocorticoid-induced osteoporosis in patients with complex inflammatory disease
• Osteoporosis with suspected inflammatory arthritis

Orthopedic referral:

• Acute fracture management (hip, vertebral with instability)
• Consideration of vertebroplasty/kyphoplasty for painful vertebral fractures not responding to conservative care
• Atypical femur fracture (prodromal thigh pain on bisphosphonates)

Physical therapy referral:

• Fall prevention and balance training
• Post-fracture rehabilitation
• Exercise prescription for patients unsure how to exercise safely

Urgency levels#

Smartphrase snippets#

New osteoporosis diagnosis, starting treatment: Osteoporosis diagnosed with T-score [X] at [site], FRAX 10-year hip risk [X]%. Starting alendronate 70mg weekly with calcium/vitamin D. Reviewed proper administration and fall prevention; DEXA in 2 years.

Osteoporosis on treatment, stable: Osteoporosis on alendronate × [X] years with stable BMD (T-score [X]). No fractures, tolerating medication well. Continue current regimen; will reassess for drug holiday at 5-year mark.

Drug holiday initiation: Osteoporosis treated with alendronate × 5 years, T-score improved to [X], no fractures. Initiating drug holiday per guidelines. Continue calcium/vitamin D and fall prevention; DEXA in 2-3 years.

Vertebral compression fracture, acute: Acute vertebral compression fracture at [level]. Pain managed with [acetaminophen/short-term NSAID], mobility encouraged. Starting osteoporosis treatment with [medication]; follow-up in 1 week.

Related pages#

• Back Pain (complaint) — includes vertebral compression fracture evaluation and management
• Falls: MSK Injury Evaluation (complaint) — post-fall fracture assessment in older adults
• Hip Pain (complaint) — includes hip fracture evaluation
• Osteoarthritis (problem) — often comorbid; both increase with age; fall prevention relevant to both
• Type 2 Diabetes (problem) — diabetes increases fracture risk; SGLT2 inhibitors may affect bone
• Hypothyroidism (problem) — overtreatment causes bone loss; monitor TSH